Phase III Tropion‑Breast02 demonstrated a 43% reduction in progression/death risk versus chemotherapy, with median overall survival improved by five months in first-line metastatic TNBC. Objective ...
Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (LSE/STO/NYSE: AZN) Datroway® (datopotamab deruxtecan-dlnk) has been approved in the U.S. for the treatment of adult patients with unresectable or ...
AstraZeneca and Daiichi Sankyo’s DATROWAY® (datopotamab deruxtecan-dlnk) has been approved in the US for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer ...
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the ...
Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates, today announced positive ...
Professional antigen-presenting cells—monocytes and macrophages—engulf these proteins, digest them into short peptide ...
The Food and Drug Administration (FDA) on May 22, 2026, approved Datroway (datopotamab deruxtecan-dlnk) for adult patients ...
CTX-8371, a novel dual checkpoint blocker that simultaneously targets the programmed death receptor PD-1 and its ligand PD-L1, demonstrated ...
The FDA has approved datopotamab deruxtecan (Dato-DXd, Datroway, Daiichi Sankyo) for the treatment of patients with ...
The TROP2 battle in first-line triple-negative breast cancer has officially kicked off. | A three-way battle among TROP2 ADCs ...
Conventional immune checkpoint inhibitors, such as anti-PD-1/PD-L1 and anti-CTLA-4 antibodies, can reinvigorate T cells but ...
The TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) demonstrated a statistically significant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results